Closure Medical Adhering To Product Diversification Strategy
This article was originally published in The Gray Sheet
Executive SummaryClosure Medical intends to pursue use of the firm's cyanoacrylate technology for internal adhesive applications such as small and large vessel anastomosis.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.